We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gene Blocking Fails to Stop Tumor Growth

By Biotechdaily staff writers
Posted on 19 Jan 2005
Cancer researchers have found that blocking genes to prevent tumor growth is only temporarily successful, as cells that survive the treatment grow back in a manner that is often no longer regulated by the gene.

Investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA; www.med.upenn.edu) worked with a mouse model to study the effect of blocking c-MYC regulation on mammary cancer. More...
C-Myc, a proto-oncogene located at 8q24, is a member of the Myc gene family that also includes the closely related N-Myc, L-Myc, P-Myc, R-Myc, S-Myc, and B-Myc genes. C-Myc spans 6-7 kb of genomic DNA, and codes for 439 amino acids. The C-Myc gene encodes a 66 kDa nuclear DNA-binding protein that regulates gene transcription and is responsible for growth control and cell cycle progression. The location of the C-Myc gene has been identified as one of the three most commonly amplified genomic regions in breast cancer, and C-Myc overexpression has been described in 70-100% of breast cancer tissues.

Previous research had suggested that preventing C-Myc expression would stop the growth of mammary cancers. However, results published in the December 2004 issue of Cancer Cell revealed that 50% of c-Myc-induced mammary cancers were able to grow in a mouse model lacking c-Myc expression. In addition, residual cancer cells remained from virtually all tumors that did regress, and these residual cells rapidly recovered their malignant properties following c-MYC reactivation or spontaneously recurred in a MYC-independent manner.

Senior author Dr. Lewis A. Chodosh, associate professor of cancer biology and medicine at the University of Pennsylvania School of Medicine, explained, "When physicians apply a selective pressure to a tumor by blocking an oncogenic pathway, cells escape. They find a back door and progress to a more aggressive state that becomes independent of that pathway.”




Related Links:
University of Pennsylvania School of Medicine

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LIAISON Murex Anti-HDV Immunoassay is the first fully automated FDA-authorized immunoassay for HDV detection in the U.S. (Photo courtesy of Diasorin)

Fully Automated Immunoassay Test Detects HDV Co‑Infection and Super-Infection

Hepatitis delta, also known as hepatitis D, is caused by the hepatitis delta virus (HDV). It is a viral liver infection that can result in one of the most severe forms of viral hepatitis.... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Industry experts gather at WHX Labs Dubai to discuss how leadership must adapt as AI and automation transform the laboratory (Photo courtesy of Shutterstock)

WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories

WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.